Novo Nordisk's Wegovy is experiencing accelerating uptake, with investor sentiment rising as the treatment opens access to a previously untapped pool of obesity patients. With no supply or regulatory constraints in sight, market analysts project further growth in prescriptions, suggesting additional upward momentum for $NVO stock as optimism over continued expansion gains traction.